154 related articles for article (PubMed ID: 25711229)
1. Co-Expression of p16, Ki67 and COX-2 Is Associated with Basal Phenotype in High-Grade Ductal Carcinoma In Situ of the Breast.
Perez AA; Balabram D; Rocha RM; da Silva Souza Á; Gobbi H
J Histochem Cytochem; 2015 Jun; 63(6):408-16. PubMed ID: 25711229
[TBL] [Abstract][Full Text] [Related]
2. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.
Kerlikowske K; Molinaro AM; Gauthier ML; Berman HK; Waldman F; Bennington J; Sanchez H; Jimenez C; Stewart K; Chew K; Ljung BM; Tlsty TD
J Natl Cancer Inst; 2010 May; 102(9):627-37. PubMed ID: 20427430
[TBL] [Abstract][Full Text] [Related]
3. COX-2, p16 and Ki67 expression in DCIS, microinvasive and early invasive breast carcinoma with extensive intraductal component.
Bartova M; Ondrias F; Muy-Kheng T; Kastner M; Singer Ch; Pohlodek K
Bratisl Lek Listy; 2014; 115(7):445-51. PubMed ID: 25077370
[TBL] [Abstract][Full Text] [Related]
4. Identification of a basal-like subtype of breast ductal carcinoma in situ.
Livasy CA; Perou CM; Karaca G; Cowan DW; Maia D; Jackson S; Tse CK; Nyante S; Millikan RC
Hum Pathol; 2007 Feb; 38(2):197-204. PubMed ID: 17234468
[TBL] [Abstract][Full Text] [Related]
5. Her2 and Ki67 Biomarkers Predict Recurrence of Ductal Carcinoma in Situ.
Davis JE; Nemesure B; Mehmood S; Nayi V; Burke S; Brzostek SR; Singh M
Appl Immunohistochem Mol Morphol; 2016 Jan; 24(1):20-5. PubMed ID: 26317313
[TBL] [Abstract][Full Text] [Related]
6. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
Steinman S; Wang J; Bourne P; Yang Q; Tang P
Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical profile of high-grade ductal carcinoma in situ of the breast.
Perez AA; Rocha RM; Balabram D; Souza Áda S; Gobbi H
Clinics (Sao Paulo); 2013 May; 68(5):674-8. PubMed ID: 23778408
[TBL] [Abstract][Full Text] [Related]
8. Expression of p16 and pRB in invasive breast cancer.
Shin E; Jung WH; Koo JS
Int J Clin Exp Pathol; 2015; 8(7):8209-17. PubMed ID: 26339389
[TBL] [Abstract][Full Text] [Related]
9. Is there 'progression through grade' in ductal invasive breast cancer?
Schymik B; Buerger H; Krämer A; Voss U; van der Groep P; Meinerz W; van Diest PJ; Korsching E
Breast Cancer Res Treat; 2012 Oct; 135(3):693-703. PubMed ID: 22886478
[TBL] [Abstract][Full Text] [Related]
10. Most basal-like breast carcinomas demonstrate the same Rb-/p16+ immunophenotype as the HPV-related poorly differentiated squamous cell carcinomas which they resemble morphologically.
Subhawong AP; Subhawong T; Nassar H; Kouprina N; Begum S; Vang R; Westra WH; Argani P
Am J Surg Pathol; 2009 Feb; 33(2):163-75. PubMed ID: 18936692
[TBL] [Abstract][Full Text] [Related]
11. Coexisting ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast cancer.
Wong H; Lau S; Leung R; Chiu J; Cheung P; Wong TT; Liang R; Epstein RJ; Yau T
Med Oncol; 2012 Sep; 29(3):1536-42. PubMed ID: 21983862
[TBL] [Abstract][Full Text] [Related]
12. 17 beta-Hydroxysteroid dehydrogenase type 1 and type 2 in ductal carcinoma in situ and intraductal proliferative lesions of the human breast.
Ariga N; Moriya T; Suzuki T; Kimura M; Ohuchi N; Satomi S; Sasano H
Anticancer Res; 2000; 20(2B):1101-8. PubMed ID: 10810403
[TBL] [Abstract][Full Text] [Related]
13. Comparison of nuclear grade and immunohistochemical features in situ and invasive components of ductal carcinoma of breast.
Aguiar FN; Mendes HN; Bacchi CE; Carvalho FM
Rev Bras Ginecol Obstet; 2013 Mar; 35(3):97-102. PubMed ID: 23538467
[TBL] [Abstract][Full Text] [Related]
14. Preoperative ultrasound radiomics analysis for expression of multiple molecular biomarkers in mass type of breast ductal carcinoma in situ.
Wu L; Zhao Y; Lin P; Qin H; Liu Y; Wan D; Li X; He Y; Yang H
BMC Med Imaging; 2021 May; 21(1):84. PubMed ID: 34001017
[TBL] [Abstract][Full Text] [Related]
15. Aldehyde dehydrogenase 1 expression correlates with the invasion of breast cancer.
Pan H; Wu N; Huang Y; Li Q; Liu C; Liang M; Zhou W; Liu X; Wang S
Diagn Pathol; 2015 Jun; 10():66. PubMed ID: 26070788
[TBL] [Abstract][Full Text] [Related]
16. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
17. Changes in intrinsic subtype of breast cancer during tumor progression in the same patient.
Kim C; Lee J; Lee W; Kim A
Int J Clin Exp Pathol; 2015; 8(11):15184-90. PubMed ID: 26823864
[TBL] [Abstract][Full Text] [Related]
18. Co-expression of p16 and p53 characterizes aggressive subtypes of ductal intraepithelial neoplasia.
Bechert C; Kim JY; Tramm T; Tavassoli FA
Virchows Arch; 2016 Dec; 469(6):659-667. PubMed ID: 27664050
[TBL] [Abstract][Full Text] [Related]
19. Breast density, scintimammographic (99m)Tc(V)DMSA uptake, and calcitonin gene related peptide (CGRP) expression in mixed invasive ductal associated with extensive in situ ductal carcinoma (IDC + DCIS) and pure invasive ductal carcinoma (IDC): correlation with estrogen receptor (ER) status, proliferation index Ki-67, and histological grade.
Papantoniou V; Sotiropoulou E; Valsamaki P; Tsaroucha A; Sotiropoulou M; Ptohis N; Stipsanelli A; Dimitrakakis K; Marinopoulos S; Tsiouris S; Antsaklis A
Breast Cancer; 2011 Oct; 18(4):286-91. PubMed ID: 20143189
[TBL] [Abstract][Full Text] [Related]
20. Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort study.
Zhou W; Jirström K; Johansson C; Amini RM; Blomqvist C; Agbaje O; Wärnberg F
BMC Cancer; 2010 Nov; 10():653. PubMed ID: 21118480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
